[go: up one dir, main page]

NO20084590L - Styrylpyridinderivater og deres anvendelse til binding og avbilding av amyloidplakker - Google Patents

Styrylpyridinderivater og deres anvendelse til binding og avbilding av amyloidplakker

Info

Publication number
NO20084590L
NO20084590L NO20084590A NO20084590A NO20084590L NO 20084590 L NO20084590 L NO 20084590L NO 20084590 A NO20084590 A NO 20084590A NO 20084590 A NO20084590 A NO 20084590A NO 20084590 L NO20084590 L NO 20084590L
Authority
NO
Norway
Prior art keywords
imaging
binding
pyridine derivatives
amyloid plaques
compounds
Prior art date
Application number
NO20084590A
Other languages
English (en)
Other versions
NO342090B1 (no
Inventor
Hank F Kung
Mei-Ping Kung
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of NO20084590L publication Critical patent/NO20084590L/no
Publication of NO342090B1 publication Critical patent/NO342090B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Denne oppfinnelsen vedrører en fremgangsmåte for avbilding av amyloidavsetninger, og styrylpyridinforbindel-ser og fremgangsmåter for fremstilling av radioaktivt merkede styrylpyridin-forbindelser som kan anvendes ved avbilding av amyloidavsetninger. Denne oppfinnelsen vedrører også forbindelser og fremgangsmåter for fremstiling av forbindelser for inhibering av aggre-gasjonen av amyloidproteiner for å danne amyloidavsetninger, og en fremgangsmåte for avlevering av et terapeutisk middel til amyloidavsetninger,
NO20084590A 2006-03-30 2008-10-29 Styrylpyridinderivater og deres anvendelse til binding og avbilding av amyloidplakker NO342090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78715606P 2006-03-30 2006-03-30
PCT/US2007/007400 WO2007126733A2 (en) 2006-03-30 2007-03-26 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques

Publications (2)

Publication Number Publication Date
NO20084590L true NO20084590L (no) 2008-12-29
NO342090B1 NO342090B1 (no) 2018-03-19

Family

ID=38326579

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20084590A NO342090B1 (no) 2006-03-30 2008-10-29 Styrylpyridinderivater og deres anvendelse til binding og avbilding av amyloidplakker
NO2018030C NO2018030I1 (no) 2006-03-30 2018-09-11 Florbetapir (18F)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2018030C NO2018030I1 (no) 2006-03-30 2018-09-11 Florbetapir (18F)

Country Status (34)

Country Link
US (3) US7687052B2 (no)
EP (3) EP2363391A1 (no)
JP (1) JP5290954B2 (no)
KR (1) KR101376807B1 (no)
CN (1) CN101522624B (no)
AT (1) ATE539060T1 (no)
AU (1) AU2007243712B2 (no)
BR (1) BRPI0710225B1 (no)
CA (1) CA2644530C (no)
CR (1) CR10329A (no)
CY (3) CY1113048T1 (no)
DK (2) DK1999109T3 (no)
EA (1) EA017898B1 (no)
EC (1) ECSP088783A (no)
ES (2) ES2378785T3 (no)
FR (1) FR13C0034I2 (no)
GT (1) GT200800201A (no)
HR (2) HRP20120135T1 (no)
HU (2) HUE032660T2 (no)
IL (1) IL193567A (no)
LT (1) LT2363392T (no)
LU (1) LU92232I2 (no)
MX (1) MX2008012527A (no)
NO (2) NO342090B1 (no)
NZ (1) NZ570887A (no)
PL (2) PL1999109T3 (no)
PT (2) PT1999109E (no)
RS (2) RS52222B (no)
SG (1) SG173338A1 (no)
SI (2) SI2363392T1 (no)
TW (1) TWI399366B (no)
UA (1) UA97802C2 (no)
WO (1) WO2007126733A2 (no)
ZA (1) ZA200807955B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5290954B2 (ja) * 2006-03-30 2013-09-18 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用
WO2009004914A1 (ja) * 2007-07-04 2009-01-08 Tohoku University フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
CN102271716B (zh) * 2008-12-31 2014-11-19 阿维德放射性药品公司 由甲苯磺酸酯前体合成18f-放射性标记的苯乙烯基吡啶及其稳定的药物组合物
CN102471177A (zh) * 2009-07-10 2012-05-23 拜耳医药股份有限公司 低至中压液相色谱在放射性示踪剂纯化中的应用
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
SG181903A1 (en) * 2009-12-23 2012-07-30 Piramal Imaging Sa Formulations suitable for pet imaging with hydrophobic pet agents
WO2011141515A1 (en) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Diagnostic agents for amyloid beta imaging
US20140012032A1 (en) * 2010-06-04 2014-01-09 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
TWI504414B (zh) 2010-06-04 2015-10-21 Bayer Schering Pharma Ag 生產Ｆ－１８標記之Ａβ配位體之方法
BR112012030946A2 (pt) 2010-06-04 2016-11-01 Piramal Imaging Sa método para a produção de ligante para amiloide beta marcado com f-18
HRP20171397T4 (hr) 2010-06-04 2019-11-15 Life Molecular Imaging Sa Postupak proizvodnje liganada amiloida beta obilježenih s f-18
CN101891674B (zh) * 2010-06-24 2012-11-14 山东大学 4-苯乙烯基吡啶类化合物及其制备方法与应用
WO2012051170A2 (en) * 2010-10-12 2012-04-19 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phingylbenzothiazole, stilbene, or biphenylalkyne derivatives
US20140079635A1 (en) * 2011-03-30 2014-03-20 Case Western Reserve University Molecular probes for detecting lipid composition
CN106729771A (zh) 2011-04-21 2017-05-31 加利福尼亚大学董事会 官能化磁性纳米颗粒及在淀粉样沉积物和神经原纤维缠结成像中用途
SG11201401640QA (en) 2011-10-19 2014-07-30 Piramal Imaging Sa IMPROVED METHOD FOR PRODUCTION OF F-18 LABELED Aß LIGANDS
BR112014024997B1 (pt) 2012-04-10 2021-03-09 Lantheus Medical Imaging, Inc. métodos de síntese radiofarmacêutica
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP6041751B2 (ja) * 2013-05-07 2016-12-14 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
JP2014218454A (ja) * 2013-05-07 2014-11-20 日本メジフィジックス株式会社 スチリルピリジン誘導体化合物
CN103645254B (zh) * 2013-11-28 2015-01-07 江苏省原子医学研究所 一种Aβ斑块显像剂前体AV45的含量分析方法
PL3143011T3 (pl) 2014-05-13 2021-07-19 F. Hoffmann-La Roche Ag Deuterowane związki heterocykliczne i ich zastosowanie jako środki obrazujące
US10478513B2 (en) 2015-08-18 2019-11-19 The Regents Of The University Of Califonia Nitroxide containing amyloid binding agents for imaging and therapeutic uses
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
CN108299287A (zh) * 2018-01-02 2018-07-20 北京师范大学 与Aβ斑块具有高亲和力的N2S2类吡啶基苯乙烯化合物
CN114805190A (zh) * 2022-06-08 2022-07-29 吉林大学第一医院 一种甲基苯胺类Aβ蛋白显像剂的双柱合成方法
CN120187703A (zh) 2022-11-14 2025-06-20 伊莱利利公司 氟贝他吡前体av-105的多晶型物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000963A1 (fr) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Composes de styryle et leur utilisation comme medicaments
JPH0545875A (ja) * 1991-08-08 1993-02-26 Konica Corp 感光性組成物
US6020436A (en) * 1993-03-09 2000-02-01 The Chromaline Corporation Photosensitive resin composition
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU2001239544A1 (en) * 2000-03-22 2001-10-03 Bf Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
US8007954B2 (en) 2000-11-09 2011-08-30 The Trustees Of The University Of Pennsylvania Use of sulfur-containing fuels for direct oxidation fuel cells
JP2002182254A (ja) 2000-12-18 2002-06-26 Fuji Photo Film Co Ltd 非線形光学材料とその製造方法
CN101003526B (zh) * 2001-08-27 2012-02-22 宾夕法尼亚州大学理事会 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途
CA2488273A1 (en) 2002-06-06 2003-12-18 The Trustees Of The University Of Pennsylvania Ceramic anodes and method of producing the same
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
JP4482352B2 (ja) 2004-03-11 2010-06-16 本田技研工業株式会社 固体高分子型燃料電池
US7858072B2 (en) * 2004-12-17 2010-12-28 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
SI2213652T1 (sl) * 2004-12-17 2015-03-31 The Trustees Of The University Of Pennsylvania Derivati stilbena in njihova uporaba za vezavo in prikaz amiloidnih plakov
JP2008546804A (ja) * 2005-06-24 2008-12-25 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 造影剤として用いるためのリガンドの放射性標識ペグ化
JP5290954B2 (ja) * 2006-03-30 2013-09-18 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用
US20080253967A1 (en) 2007-04-13 2008-10-16 Kung Hank F Halo-Stilbene Derivatives And Their Use For Binding And Imaging Of Amyloid Plaques

Also Published As

Publication number Publication date
CN101522624A (zh) 2009-09-02
CA2644530A1 (en) 2007-11-08
EP2363392B1 (en) 2017-05-03
CY2013024I2 (el) 2015-11-04
US8506929B2 (en) 2013-08-13
HRP20120135T1 (hr) 2012-03-31
TWI399366B (zh) 2013-06-21
ECSP088783A (es) 2008-10-31
TW200838852A (en) 2008-10-01
EA200870389A1 (ru) 2009-04-28
US20130129624A1 (en) 2013-05-23
CA2644530C (en) 2015-05-19
ES2378785T3 (es) 2012-04-17
JP5290954B2 (ja) 2013-09-18
JP2009532349A (ja) 2009-09-10
CN101522624B (zh) 2013-11-06
SG173338A1 (en) 2011-08-29
SI2363392T1 (sl) 2017-09-29
ZA200807955B (en) 2012-11-28
US20080038195A1 (en) 2008-02-14
LU92232I9 (no) 2019-01-15
EP1999109A2 (en) 2008-12-10
CY2013024I1 (el) 2015-11-04
AU2007243712B2 (en) 2013-01-10
PT1999109E (pt) 2012-03-16
WO2007126733A2 (en) 2007-11-08
KR20080106564A (ko) 2008-12-08
WO2007126733A3 (en) 2008-03-06
IL193567A (en) 2014-03-31
EA017898B1 (ru) 2013-04-30
ES2628882T3 (es) 2017-08-04
ATE539060T1 (de) 2012-01-15
FR13C0034I1 (no) 2013-08-09
NZ570887A (en) 2011-05-27
GT200800201A (es) 2009-08-20
IL193567A0 (en) 2009-05-04
LT2363392T (lt) 2017-07-25
FR13C0034I2 (fr) 2014-03-07
SI1999109T1 (sl) 2012-04-30
US7687052B2 (en) 2010-03-30
CY1113048T1 (el) 2015-11-04
HUE032660T2 (en) 2017-10-30
HRP20170857T1 (hr) 2017-12-01
US8840866B2 (en) 2014-09-23
EP2363391A1 (en) 2011-09-07
DK2363392T3 (en) 2017-07-03
UA97802C2 (uk) 2012-03-26
KR101376807B1 (ko) 2014-03-20
EP1999109B1 (en) 2011-12-28
EP2363392A1 (en) 2011-09-07
BRPI0710225A2 (pt) 2011-08-02
US20090123369A1 (en) 2009-05-14
DK1999109T3 (da) 2012-04-02
MX2008012527A (es) 2008-10-14
CR10329A (es) 2008-10-29
RS56171B1 (sr) 2017-11-30
RS52222B (sr) 2012-10-31
HUS1300028I1 (hu) 2017-08-28
AU2007243712A1 (en) 2007-11-08
PL2363392T3 (pl) 2017-10-31
BRPI0710225B1 (pt) 2021-07-13
PL1999109T3 (pl) 2012-05-31
PT2363392T (pt) 2017-06-15
NO2018030I1 (no) 2018-09-11
CY1119048T1 (el) 2018-01-10
LU92232I2 (fr) 2013-08-26
NO342090B1 (no) 2018-03-19

Similar Documents

Publication Publication Date Title
NO20084590L (no) Styrylpyridinderivater og deres anvendelse til binding og avbilding av amyloidplakker
NO20073650L (no) Stilbenderivater og deres anvendelse til binding og avbilding av amyloidplakker
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
NO332405B1 (no) Forbindelse av 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling, deres anvendelse til fremstilling av farmasoytiske midler for behandling av inflammatorisk sykdom og farmasoytisk preparat omfattende forbindelsen.
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20092567L (no) Acetylendenvater og deres anvendelse til binding og avbilding av amyloidplakker
NO20084435L (no) C-MET proteinkinaseinhibitorer
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
HK1244232A1 (zh) 用於治疗肺纤维化的血管紧张素ii受体激动剂
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20090268L (no) Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
WO2008061108A3 (en) Phthalazine derivatives
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ
WO2006078384A3 (en) Stilbene derivatives and their use
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
WO2009108755A3 (en) Pharmaceutical combinations for the treatment of cancer
NO20072209L (no) Nye kromen-2-on-derivater og deres anvendelse som monoaminnevrotransmittergjenopptaksinhibitorer.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: FLORBETAPIR (18F); NORWEGIAN MARKETING AUTHORISATION: 2013.01.14 , NO , EU/1/12/805 , AMYVID

Spc suppl protection certif: 2018030

Filing date: 20180911

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: FLORBETAPIR (18F); REG. NO/DATE: 20130117

Spc suppl protection certif: 2018030

Filing date: 20180911

Extension date: 20280117